A Phase 1B study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF- mutant metastatic melanoma (The CELEBRATE study)

  • Shackleton, Mark (Primary Chief Investigator (PCI))
  • Hawkins, Cheryl-Ann (Project Manager)

Project: Research

Project Details

Effective start/end date5/05/2131/12/24


  • Metastatic Melanoma
  • Oncology
  • Clinical trial